United States

People: GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

17 Nov 2017
Change (% chg)

$-0.13 (-0.37%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Vallance, Patrick 

Mr. Patrick Vallance is no longer President - R&D, Executive Director of Glaxosmithkline Plc, effective March 31, 2018. Patrick joined GSK in 2006 as Head of Drug Discovery and was subsequently appointed Senior Vice President, Medicines Discovery and Development. He has been a member of GSK’s Corporate Executive Team since 2010 and was appointed President, Pharmaceuticals R&D in January 2012. Patrick joined the GSK Board on 1 January 2017. Prior to joining GSK, Patrick was a clinical academic and, as Professor of Medicine, led the Division of Medicine at University College London. He has over 20 years’ experience of research clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999. Patrick is a Non-Executive Director of Genome Research Limited and UK Biobank.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --